Serum concentrations of matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1 and A2-macroglobulin in healthy subjects after supplementation with different doses of marine n-3 fatty acids

Cellular and Molecular Biology

Volumn 56, Issue 1, 2010, Pages 102-109

  Vogt, J ^a   Andersen, V L ^a   Andreasen, A ^a   Obel, T ^a   Christensen, J H ^a   Schmidt, E B ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

2 macroglobulin; Atherosclerosis; Matrix metalloproteinase 9; MMP 9; n 3 polyunsaturated fatty acid; n 3 PUFA; TIMP 1; Tissue inhibitor of matrix metalloproteinase 1

Indexed keywords

ALPHA 2 MACROGLOBULIN; DOCOSAHEXAENOIC ACID; FISH OIL; GELATINASE B; ICOSAPENTAENOIC ACID; MARINE N 3 POLYUNSATURATED FATTY ACID; OLIVE OIL; POLYUNSATURATED FATTY ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; OMEGA 3 FATTY ACID;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE COMPARISON; FEMALE; HEART RATE VARIABILITY; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED;

ADULT; ALPHA-MACROGLOBULINS; ANALYSIS OF VARIANCE; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77953638752     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.1170/T883     Document Type: Article

References (62)

1. Aarsetoy, H., Brugger-Andersen, T., Hetland, O., Grundt, H. and Nilsen, D.W., Long term influence of regular intake of high dose n-3 fatty acids on CD40-ligand, pregnancy- associated plasma protein A and matrix metalloproteinase-9 following acute myocardial infarction. Thromb. Haemost. 2006, 95: 329-336.
2. Baker, A.H., Edwards, D.R. and Murphy, G., Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell. Sci. 2002, 115: 3719-3727.
3. Beaudeux, J.L., Giral, P., Bruckert, E., Bernard, M., Foglietti, M.J. and Chapman, M.J., Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis 2003, 169: 139-146.
4. Bonnema, D.D., Webb, C.S., Pennington, W.R., Stroud, R.E., Leonardi, A.E. and Clark, L.L., Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J. Card. Fail. 2007, 13: 530-540.
5. Calder, P.C., n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin. Sci. (Lond) 2004, 107: 1-11.
6. Christensen, J.H., Christensen, M.S., Dyerberg, J. and Schmidt, E.B., Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. American Journal of Clinical Nutrition 1999, 70: 331-337.
7. Das UN., Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot. Essent. Fatty Acids 2000, 63: 351-362.
8. Delbosc, S., Glorian, M., Le Port, A.S., Bereziat, G., Andreani, M. and Limon, I., The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9. Am. J. Pathol. 2008, 172: 1430-1440.
9. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354: 447-455.
10. Ferrante, A., Thong, Y.H., A rapid one step procedure for purification of mononuclear and polymorphonuclear leucocytes from human blood using a modification of the hypaque-ficoll technique. Journal of immunological methods 1978, 24: 389-393.
11. Frederik, J.G.M., Thomas, G.W., Gas chromatography-mass spectrometry method for determination of phospholipid peroxides; I. Transesterification to form methyl esters. Journal of free radicals in biology and medicine 1985, 4: 215-225.
12. Furenes, E.B., Seljeflot, I., Solheim, S., Hjerkinn, E.M. and Arnesen, H., Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease. Scand. J. Clin. Lab. Invest. 2008, 68: 177-184.
13. George, S.J., Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr. Opin. Lipidol. 1998, 9: 413-423.
14. Glowinska-Olszewska, B. and Urban, M., Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents. Metabolism 2007, 56: 799-805.
15. Hobeika, M.J., Thompson, R.W., Muhs, B.E., Brooks, P.C. and Gagne, P.J., Matrix metalloproteinases in peripheral vascular disease. J. Vasc. Surg. 2007, 45: 849-857.
16. Hooper, L., Thompson, R.L., Harrison, R.A., Summerbell, C.D., Ness, A.R. and Moore, H.J., Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006, 332: 752-760.
17. Iso, H., Kobayashi, M., Ishihara, J., Sasaki, S., Okada, K. and Kita, Y., Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006, 113: 195-202.
18. Jiang, X., Zeng, H.S., Guo, Y., Zhou, Z.B., Tang, B.S. and Li, F.K., The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin. Med. J. (Engl ) 2004, 117: 1825-1829.
19. Kai, H., Ikeda, H., Yasukawa, H., Kai, M., Seki, Y. and Kuwahara, F., Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 1998, 32: 368-372.
20. Kalela, A., Laaksonen, R., Lehtimaki, T., Koivu, T.A., Hoyhtya, M. and Janatuinen, T., Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am. J. Cardiol. 2001, 88: 173-175.
21. Laimer, M., Kaser, S., Kranebitter, M., Sandhofer, A., Muhlmann, G. and Schwelberger, H., Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. Int. J. Obes. (Lond) 2005, 29: 498-501.
22. Luu, N.T., Madden, J., Calder, P.C., Grimble, R.F., Shearman, C.P. and Chan, T., Dietary supplementation with fish oil modifies the ability of human monocytes to induce an inflammatory response. J. Nutr. 2007, 137: 2769-2774.
23. Madsen, T., Christensen, J.H., Blom, M. and Schmidt, E.B., The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: a dose-response study. Br. J. Nutr. 2003, 89: 517-522.
24. Matsumoto, M., Sata, M., Fukuda, D., Tanaka, K., Soma, M. and Hirata, Y., Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. Atherosclerosis 2008, 197: 524-533.
25. Miles, E.A., Zoubouli, P. and Calder, P.C., Differential anti-inflammatory effects of phenolic compounds from extra virgin olive oil identified in human whole blood cultures. Nutrition 2005, 21:389-394.
26. Nagase, H., Visse, R. and Murphy, G., Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006, 69: 562-573.
27. Newby, A.C., Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr. Opin. Lipidol. 2006, 17: 556-561.
28. Nordskog, B.K., Blixt, A.D., Morgan, W.T., Fields, W.R. and Hellmann, G.M., Matrix-degrading and pro-inflammatory changes in human vascular endothelial cells exposed to cigarette smoke condensate. Cardiovasc. Toxicol. 2003, 3: 101-117.
29. Packard, RR. and Libby, P., Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin. Chem. 2008, 54: 24-38.
30. Raffetto, J.D. and Khalil, R.A., Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem. Pharmacol. 2008, 75: 346-359.
31. Schmidt, E.B., Arnesen, H., Christensen, J.H., Rasmussen, L.H., Kristensen, S.D. and De, C.R., Marine n-3 polyunsaturated fatty acids and coronary heart disease: Part II. clinical trials and recommendations. Thromb. Res. 2005, 115: 257-262.
32. Schmidt, E.B., Arnesen, H., De, C.R., Rasmussen, L.H. and Kristensen, S.D., Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb. Res. 2005, 115: 163-170.
33. Schmidt, E.B., Pedersen, J.O., Varming, K., Ernst, E., Jersild, C. and Grunnet, N., n-3 fatty acids and leukocyte chemotaxis. Effects in hyperlipidemia and dose-response studies in healthy men. Arteriosclerosis and Thrombosis 1991, 11: 429-435.
34. Schmidt, E.B., Rasmussen, L.H., Rasmussen, J.G., Joensen, A.M., Madsen, M.B. and Christensen, J.H., Fish, marine n-3 polyunsaturated fatty acids and coronary heart disease: a minireview with focus on clinical trial data. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75: 191-195.
35. Schmidt, E.B., Varming, K., Ernst, E., Madsen, P. and Dyerberg, J., Dose-response studies on the effect of n-3 polyunsaturated fatty acids on lipids and haemostasis. Thromb. Haemost. 1990, 63: 1-5.
36. Seagrave, J., Barr, E.B., March, T.H. and Nikula, K.J., Effects of cigarette smoke exposure and cessation on inflammatory cells and matrix metalloproteinase activity in mice. Exp. Lung. Res. 2004, 30: 1-15.
37. Sundstrom, J. and Vasan, R.S., Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr. Opin. Lipidol. 2006, 17: 45-53.
38. Tayebjee, M.H., Lip, G.Y., Blann, A.D. and Macfadyen, R.J., Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb. Res. 2005, 115: 205-210.
39. Tayebjee, M.H., Lip, G.Y., Tan, K.T., Patel, J.V., Hughes, E.A. and Macfadyen, R.J., Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am. J. Cardiol. 2005, 96: 339-345.
40. Tayebjee, M.H., Nadar, S., Blann, A.D., Gareth, B.D., Macfadyen, R.J. and Lip, G.Y., Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am. J. Hypertens. 2004, 17: 764-769.
41. Thies, F., Garry, J.M., Yaqoob, P., Rerkasem, K., Williams, J. and Shearman, C.P., Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet 2003, 361: 477-485.
42. Varming, K., Schmidt, E.B., Grunnet, N., Jersild, C. and Dyerberg, J., The effect of n-3 fatty acids on neutrophil chemiluminescence. Scand. J. Clin. Lab. Invest. 1995, 55: 47-52.
43. Visse, R. and Nagase, H., Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92: 827-839.
44. Weinkouff, P.M., Koenig, W., Hagstrup, C.J. and Berg, S.E., The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA(2) in healthy adults. Eur. J. Nutr. 2008 Nov 21.
45. Xu, Z., Zhao, S., Zhou, H., Ye, H. and Li, J., Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome. Clin. Chem. 2004, 50: 750-753.
46. Yasmin, McEniery, C.M., O'Shaughnessy, K.M., Harnett, P., Arshad, A. and Wallace, S., Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler. Thromb. Vasc. Biol. 2006, 26: 1799-1805.
47. Yasmin, McEniery, C.M., Wallace, S., Dakham, Z., Pulsalkar, P. and Maki-Petaja, K., Matrix metalloproteinase- 9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005, 25: 372.
48. Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y. and Ishikawa, Y., Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007, 369: 1090-1098.
49. Zampolli, A., Bysted, A., Leth, T., Mortensen, A., De, C.R. and Falk, E., Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models. Atherosclerosis 2006, 184: 78-85.
50. Zeng, B., Prasan, A., Fung, K.C., Solanki, V., Bruce, D. and Freedman, SB., Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005, 35: 331-335.
51. Andersen, V.L., Vogt, J., Obel, T., Christensen, J.H., Schmidt, E.B., The effect of n-3 fatty acids on plasma myeloperoxidase levels in healthy adults. Cell. Mol. Biol. 2010, 56(1): 3-9.
52. Andreasen, J. J., Aardestrup, I. V., Eschen, R. B., Obel, T., Lundbye-Christensen, S., Schmidt, E. B., Fatty acid composition of the internal mammary artery in relation to dietary intake of marine n-3 polyunsaturated fatty acids and association with flow-mediated vasodilation. Cell. Mol. Biol. 2010, 56(1): 10-17.
53. Arnesen, H., Seljeflot, I., Studies on very long chain marine n-3 fatty acids in patients with atherosclerotic heart disease with special focus on mechanisms, dosage and formulas of supplementation. Cell. Mol. Biol. 2010, 56(1): 18-27.
54. Calder, P.C., Yaqoob, P., Omega-3 (n-3) fatty acids, cardiovascular disease and stability of atherosclerotic plaques. Cell. Mol. Biol. 2010, 56(1): 28-37.
55. Petersen, M.M., Eschen, R.B., Aardestrup, I., Obel, T., Schmidt, E.B., Flow-mediated vasodilation and dietary intake of n-3 polyunsaturated acids in healthy subjects. Cell. Mol. Biol. 2010, 56(1): 38-44.
56. Eschen, O., Christensen, J.H., La rovere, M.T., Romano, P., Sala, P., Schmidt, E.B., Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure. Cell. Mol. Biol. 2010, 56(1): 45-51.
57. Isherwood, C., Wong, M., Jones, W.S., Davies, I.G., Griffin, B.A., lack of effect of cold water prawns on plasma cholesterol and lipoproteins in normo-lipidaemic men. Cell. Mol. Biol. 2010, 56(1): 52-58.
58. Massaro, M., Scoditti, E., Carluccio, M. A., Campana, M. C., De caterina, R., Omega-3 fatty acids, inflammation and angiogenesis: basic mechanisms behind the cardioprotective effects of fish and fish oils. Cell. Mol. Biol. 2010, 56(1): 59-82.
59. Mori, T. A., Omega-3 fatty acids and blood pressure. Cell. Mol. Biol. 2010, 56(1): 83-92.
60. Von Schacky, C., Omega-3 fatty acids vs. cardiac disease - the contribution of the omega-3 index. Cell. Mol. Biol. 2010, 56(1): 93-101.
61. Marchioli, R., Silletta, M.G., Levantesi, G., Pioggiarella, R., Tognoni, G., N-3 polyunsaturated fatty acids in heart failure: mechanisms and recent clinical evidence. Cell. Mol. Biol. 2010, 56(1): 110-130.
62. Christensen, J.H., Svensson, M., Strandhave, C., Madsen, T., Schmidt, E.B., N-3 fatty acids and cardiac autonomic function in humans. Cell. Mol. Biol. 2010, 56(1): 131-139.